About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
AMRN - Amarin Corporation p...| Previous Close | $6.48 | Open | $6.48 |
| Volume | 6.78M | Market Cap | 2.499B |
| Yield | Last Dividend |
| The Week Ahead In Biotech: Novavax Coron... | 08/02/20 |
| Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts. COVID-19 news flo... | |
| Amarin to Report Second Quarter 2020 Res... | 07/21/20 |
| DUBLIN, Ireland and BRIDGEWATER, N.J., July 21, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a??? | |
| Amarin (AMRN) stock to remain within a t... | 06/24/20 |
| The patent war between Amarin (NASDAQ: AMRN) and the generic companies for cardiovascular drug Vascepa continues to be a headwind for Amarin. Shares o... | |
| Amarin Analysts Say Vascepa Patent Settl... | 06/17/20 |
| Amarin Corporation plc (NASDAQ: AMRN ) announced late Tuesday a settlement agreement with Apotex for resolving a patent lawsuit regarding a generic ve... | |
| The Daily Biotech Pulse: Patent Win For ... | 06/17/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hour. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 16) ADC ... | |
| Amarin Announces Patent Litigation Settl... | 06/16/20 |
| DUBLIN, Ireland and BRIDGEWATER, N.J., June 16, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced today a settlement agreement w... | |
| Why Some Analysts Remain Bullish on Amar... | 06/16/20 |
| No summary available. | |
| Why Amarin (AMRN) Stock Might be a Great... | 06/09/20 |
| Amarin (AMRN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well. | |
| What Amarin Stock Investors Will Hear at... | 06/09/20 |
| No summary available. | |
| Will New Marketing Push Pump Amarin Stoc... | 06/02/20 |
| No summary available. | |
| Amarin Plans to Increase VASCEPA?? (icos... | 06/01/20 |
| Significant Opportunity Seen as Patient Visits Resume to Emphasize VASCEPA as the First and Only Drug Approved for Its Current Cardiovascular Risk Red... | |
| Potential COVID-19 Treatment Could Help ... | 05/27/20 |
| No summary available. | |
| Generic Threat To Amarin's Vascepa Overr... | 05/22/20 |
| Amarin Corporation plc (NASDAQ: AMRN ) shares, which were higher in after-hours trading Thursday following the company's announcement regarding a thir... | |
| Amarin Stock???s Potential Unhampered by... | 05/22/20 |
| No summary available. | |
| Amarin Stock Is Falling. A Competitor Go... | 05/22/20 |
| British generic drugmaker Hikma Pharmaceuticals said it had received Food and Drug Administration approval to sell a generic version of Amarin???s fis... | |
| Amarin Down 10% in Pre-Market On Generic... | 05/22/20 |
| Shares in Amarin (AMRN) are plunging 10% in Friday???s pre-market trading on the news that Hikma Pharmaceuticals (HKMPY) has received approval from th... | |
| Amarin Supports Trial to Investigate the... | 05/21/20 |
| DUBLIN, Ireland and BRIDGEWATER, N.J., May 21, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced support for a clinical??... | |
| Will Amarin Stock???s Fundamentals Outwe... | 05/19/20 |
| No summary available. | |
| Huge Sales Growth Brightens Future for A... | 05/13/20 |
| No summary available. | |
| Why an Appeals Court May Hold Key to Ama... | 05/08/20 |
| No summary available. | |
| Amarin's (AMRN) Q1 Loss In Line With Est... | 05/01/20 |
| Amarin's (AMRN) strong revenue growth in the first quarter is attributable to continued solid demand for its cardiovascular drug, Vascepa. | |
| Amarin (AMRN) Meets Earnings Estimates i... | 04/30/20 |
| Amarin's (AMRN) first quarter earnings were in line with expectations. However, sales beats estimates. Stock down. | |
| The Daily Biotech Pulse: FDA Nod For Gla... | 04/30/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 29) ??... | |
| Can Amarin Stock Overcome COVID-19 and L... | 04/28/20 |
| No summary available. | |
| Despite temporary setbacks, Amarin (AMRN... | 04/14/20 |
| Shares of Amarin Corporation plc (NASDAQ: AMRN) were up 4.6% in midday trade on Tuesday, a day after the company reported preliminary results for the ... | |
| Amarin Corporation plc (NASDAQ: AMRN) Q1... | 04/13/20 |
| Final earnings conference call transcript of Amarin Corporation plc - AMRN stock | |
| The Week Ahead In Biotech: Spotlight On ... | 04/05/20 |
| Biotech stocks went along with the broader market flow in the week ended April 3, with the COVID-19 pandemic dictating sentiment. The week witnessed a... | |
| Is Amarin (AMRN) Stock a Solid Choice Ri... | 04/02/20 |
| Amarin (AMRN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well. | |
| INVESTIGATION ALERT: The Schall Law Firm... | 03/31/20 |
| LOS ANGELES--(BUSINESS WIRE)---- $AMRN #AMRN--INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Amarin Corporation... | |
| Amarin News: AMRN Stock Plunges 71% on C... | 03/31/20 |
| Amarin (AMRN) news for Tuesday concerning a generic rival lawsuit over one of its drugs has AMRN stock taking a nosedive. | |
| Date | 2020-08-04 (BMO) | Est. (EPS/Rev.) | ($0.07)/ 149.48M |
| Actual (EPS/Rev.) | / | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Big Data Zhou | Zhou Academy | 82.00 % | Subscribe |
| Options Eagle | George | 79.00 % | Follow |
| Alpha Swing Trades | Jonathan | 68.00 % | Follow |
| Option short-term trading [Unusual] | Debashis K | 66.00 % | Subscribe |
| Swingers Corner | Akemi Mokoto | 42.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
